Celcuity Inc. filings document formal disclosures for a clinical-stage biotechnology company developing targeted oncology therapies. Recent 8-K reports cover gedatolisib and VIKTORIA-1 clinical-trial results in HR+/HER2- advanced breast cancer, FDA-related regulatory updates, financial results, Regulation FD materials, and amendments to a loan and security agreement.
Proxy materials describe annual meeting matters, director elections, auditor ratification, executive compensation votes, stock incentive plans, and employee stock purchase plan amendments. Governance filings also record board composition changes and director compensation arrangements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.46%
Tags
FAQ
How many Celcuity (CELC) SEC filings are available on StockTitan?
StockTitan tracks 64 SEC filings for Celcuity (CELC), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for Celcuity (CELC)?
The most recent SEC filing for Celcuity (CELC) was filed on June 30, 2025.